Clinical Efficacy of Acamprosate in the Treatment of Alcoholism

  • M. Soyka
Conference paper

Abstract

The pathophysiological and neurochemical basis of alcohol dependence, craving, and relapse are not yet fully understood (for review see Littleton et al. and Lovinger, this volume). However, a variety of studies implicate several neurotransmitters and receptors as very likely to be involved in the development of alcohol tolerance and dependence, including the dopaminergic and serotonergic system (DiChiara and Imperato 1988; Engel et al. 1990; LeMarquand et al. 1994: Sellers et al. 1981, 1992), opiates/endorphines, GABA, and glutamate (Littleton et al. 1991; Lovinger et al. 1989). This has led to new pharmacotherapeutic approaches in the therapy of alcoholism. In addition to chemical aversion therapy (Annis and Peachey 1992; Banys 1988; Fuller et al. 1986), tricyclic antidepressants (Soyka and Naber 1992), and lithium (Fawcett et al. 1984), various other substances have been tested in an attempt to increase abstinence rates in alcoholics, all with little or no success. More recently a variety of substances have been examined as an adjunct in relapse prevention in alcoholism; these include serotonergic substances, especially serotonin uptake inhibitors, buspirone, dopaminergic drugs, and opiate antagonists such as naltrexone and nalmefene (Amit et al. 1991; Balldin et al. 1994; Mason et al. 1994; O’Malley et al. 1992; Sellers et al. 1981; Volpicelli et al. 1992; for review see Soyka 1995). None of these compounds has so far found general exceptance as anticraving drug.

Keywords

Placebo Lithium Dopamine Serotonin Cocaine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amit Z, Smith BR, Gill KG (1991) Serotonin uptake inhibitors: effects on motivated consummatory behaviors. J Clin Psychiatry 52 [suppl 12]: 55–60PubMedGoogle Scholar
  2. Annis HM, Peachey JE (1992) The use of calcium carbimide in relapse prevention counselling: results of a randomized controlled trial. Br J Addict 87: 63–72PubMedCrossRefGoogle Scholar
  3. Aubin HJ, Lehert P, Beaupere B, Jacquemin F, Barrucand D (1994) Acamprosate tolerance in association with other medications taken during alcohol withdrawal. Multicentre trial involving 591 alcoholic patients undergoing withdrawal. Alcoologie 16: 32–41Google Scholar
  4. Balldin J, Berggren U, Bokström K, Erikkson M, Gottfries CG, Karlsson I, Walinder J (1994) Six-month open trial with zimelidine in alcohol-dependent patients: reduction in days of alcohol intake. Drug Alcohol Depend 35: 245–248PubMedCrossRefGoogle Scholar
  5. Banys P (1988) The clinical use of disulfiram (Antabuse): review. J Psychoact Drugs 20: 243–261Google Scholar
  6. Besson J, Aeby F, Kasas A, Fendl A, Lehert P (1994) Combined efficacy of acamprosate and disulfiram for enhancing abstinence of chronic alcoholic pateints during a one year post detofixication period. Neuropsychopharmacology 10.3 [Suppl 2]: 74SGoogle Scholar
  7. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P, Durlach J (1984) A homotaurine derivate reduces the voluntary intake by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 21: 787–789PubMedCrossRefGoogle Scholar
  8. Boismare F, Daoust M, Lhuintre JP, Moore N, Saligaut C, Chretien P (1986) Metaprimeinduced reduction of voluntary intake of ethanol by rats: mechanism of action. J Pharmacol 17: 170Google Scholar
  9. Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22 [suppl 1] 49–59PubMedCrossRefGoogle Scholar
  10. Daoust M, Lhuintre JP, Saligaut C, Moore N, Flipo JL, Boismare F (1987) Noraderenaline and GABA brain receptors are co-involved in the voluntary intake of ethanol by rats. Alcohol Alcohol [suppl] 1: 319–322Google Scholar
  11. Daoust M, Protais P, Boucly P, Tran G, Rinjard P, Dokhan R, Fillion G (1989) Intervention of acamprosate on serotoninergic and noradrenergic system. Alcohol Alcohol 24: 370Google Scholar
  12. Daoust M, Legrand E, Durbin P (1994) Binding characteristics of 3H-acamprosate on neuronal membrane preparations. Alcohol Clin Exp Res 18: 33A (abstract no 5.13)Google Scholar
  13. DiChiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274–5278CrossRefGoogle Scholar
  14. Durlach J, Rinjard P, Sprince H, Smith GG (1988) Similar antagonist effects of Ca N-acetyl homotaurinate on depression of motor activity and lethality induced by acetaldehyde or ethanol. Methods Find Exp Clin Pharmacol 10: 437–447PubMedGoogle Scholar
  15. Engel JA, Enerback C, Fahlke C, Hulthe H, Johannenssen K, Stevensson L, Soderpalm B (1990) Serotonergic and dopaminergic involvement in ethanol intake. In: Novel pharmacological interventions for alcoholism. Naranjo CA, Sellers EM (eds) Springer, New York Berlin Heidelberg, pp 68–82Google Scholar
  16. Fawcett J, Clark DC, Gibbons RD, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, Stutzman D (1984) Evaluation of lithium therapy for alcoholism. J Clin Psychiatry 45: 494–499PubMedGoogle Scholar
  17. Feuerlein W, Ringer C, Kuefner H, Antons K (1977) Diagnose des Alkoholismus. Der Münchner Alkoholismustest ( MALT ). Munch Med Wochenschr 119: 1275–1282Google Scholar
  18. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstamm I, Manny I, Neiderhiser D, Nocks S, Shaw JJ (1986) Disulfiram treatment of alcoholism: a Veterans Aministration cooperative study. JAMA 256: 1449–1455PubMedCrossRefGoogle Scholar
  19. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P (1991) Acamprosate and diazepam differentially modulate alcohol induced behavioral and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 26: 129–137PubMedGoogle Scholar
  20. Grant KA, Woolverton WL (1989) Reinforcing and discriminative stimulus effects of Ca-acetyl homotraurine in animals. Pharmacol Biochem Behav 32: 607–611PubMedCrossRefGoogle Scholar
  21. Gutierrez S, Daoust M, Rinjard P, Lhuintre JP, Boismare F (1987) L’acétylhomotaurinate de calcium, molécule a propriétés GABAergiques, atténue le syndrome de sevrage alcoolique chez la souris C57BL. Rev Alcool 32: 241–247Google Scholar
  22. Karler LD, Calder LD, Chaudry IA, Turkanis SA (1989) Blockade of `reverse tolerance’ to cocaine and amphetamine by MK-801. Life Sci 45: 599–606PubMedCrossRefGoogle Scholar
  23. Ladewig D, Knecht T, Lehert P et al. (1993) Acamprosat–ein stabilisierungstfaktor in der Langzeitentwöhnung von Alkoholabhangigen. Ther Umschau 59: 182–188Google Scholar
  24. Le Magnen J (1990) Effect of calcium acetyl homotaurinate on alcohol dependency. Med Chir Dig 19: 47–48Google Scholar
  25. Le Magnen J, Tran G, Durlach J, Martin C (1987b) Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 4: 97–102PubMedCrossRefGoogle Scholar
  26. Lehert P (1993) Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol [Supp1]2: 157–163Google Scholar
  27. LeMarquand D, Pihl RO, Benkelfat C (1994) Serotonin and alcohol intake, abuse, and dependence; clinical evidence. Biol Psychiatry 36: 326–337PubMedCrossRefGoogle Scholar
  28. Lesch OM, Walter H, Fischer F, Platz W, Haring C, Leitner A, Benda N (1994) New devel- opments of reducing alcohol intake. Alcohol Clin Exp Res 18: 43A (abstract No. 9.3)Google Scholar
  29. Lhuintre JP, Daoust M, Moore N, Cheretien P, Saligaut C, Tran G, Boismare F, Hillemand B (1985) Ability of calcium bis-acetyl homotaurine, a GABA agonsit, to prevent relapse in weaned alcoholics. Lancet I: 1014–1016Google Scholar
  30. Littleton JM, Brennan C, Bouchenafa O (1991) The role of calcium flux in the central nervous system actions of ethanol. Ann N Y Acad Sci 625: 388PubMedCrossRefGoogle Scholar
  31. Lovinger DM, White G, Weight FF (1989) Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243: 1721PubMedCrossRefGoogle Scholar
  32. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy ans safety of oral nalmefene HCI for alcohol dependence. Alcohol Clin Exp Res 18: 1162–1167PubMedCrossRefGoogle Scholar
  33. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881–887PubMedCrossRefGoogle Scholar
  34. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30: 239–247PubMedGoogle Scholar
  35. Pelc I, Lebon O, Verbanck P, Lehert P, Opsomer L (1992) Calcium-acetylhomotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multicenter study. In: Naranjo CA, Sellers EM (eds) Novel pharmacological interventions in alcoholism. Springer, Berlin Heidelberg New York, pp 358–352Google Scholar
  36. Pelc I, LeBon O, Verbanck P (1994) Acamprosate in the treatment of alcohol dependence: a six month post-detoxification study. Alcohol Clin Exp Res 18: 38A (abstract no 6.6)Google Scholar
  37. Pickens RW, Johanson C-E (1991) Craving: consensus of status and agenda for future research. Drug Alcohol Depend 30: 127–131CrossRefGoogle Scholar
  38. Poldrugo F, Chabac S, Lehert P (1994) Acamprosate in the long-term treatment of alcoholism: is its use recommended within the psycho-social approach? Alcohol Clin Exp Res 18: 43A (abstract no 9.2)Google Scholar
  39. Rassnick S, Damico E, Riley E, Pulvierenti L, Zieglgänsberger W, Koob GF (1992) GABA and nucleus accumbens glutamate neurotransmission modulate ethanol self-administration in rats. Ann NY Acad Sci 654: 502–555PubMedCrossRefGoogle Scholar
  40. Sass H, Soyka M, Mann K, Zieglgänsberger W (1995) Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry (in press)Google Scholar
  41. Sellers EM, Naranjo CA, Peachey JE (1981) Drugs to decrease alcohol consumption. N Engl J Med 305: 1255–1262PubMedCrossRefGoogle Scholar
  42. Sellers EM, Higgins GA, Sobell MB (1992) 5-HT and alcohol abuse. Trends Pharmacol Sci 13: 69–75CrossRefGoogle Scholar
  43. Soyka M (1995) Die Alkoholkrankheit. Chapman and Hall, WeinheimGoogle Scholar
  44. Soyka M, Naber D (1993) Antidepressiva in der Behandlung des chronischen Alkoholismus. Neurol Psychiatr 7: 213–221Google Scholar
  45. Stockwell T, Hodgson R, Edwards G, Taylor C, Rankin H (1979) The development of a questionnaire to measure severity of alcohol dependence. Br J Addict 74: 79–87CrossRefGoogle Scholar
  46. Tempesta E, Janiri L, Bignamini A (1994) The effectiveness and safety of calcium-acetylhomotaurinate (acamprosate) on the maintenance and abstinence in weaned alcoholics. Paper given at the 76s AEP congress, 18–22 September 1994, CopenhagenGoogle Scholar
  47. The Plinius Maior Society (1994) Guidelines on evaluation of treatment of alcohol dependence. Alcoholism 30 [suppl]Google Scholar
  48. Trujillo KA, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251: 85–87PubMedCrossRefGoogle Scholar
  49. Tsai G, Gastfriend DR, Coyle JT (1995) The glutamatergic basis of human alcoholism. Am J Psychiatry 152: 332–340PubMedGoogle Scholar
  50. Verma A, Kulkarni SK (1993) Role of Dl/D2 dopamine and N-methyl-D-aspartate ( NMDA) receptors in morphine tolerance and dependence in mice. Eur Neupsychopharmacol 5: 81–87CrossRefGoogle Scholar
  51. Vollpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880CrossRefGoogle Scholar
  52. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker C (1996) Acamprosate versus placebo in the long-term treatment of patients with alcohol dependence. Lancet (in press)Google Scholar
  53. Zeise ML, Kasparow S, Capogna M, Zieglgänsberger W (1993) Acamprosate (calciumhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 231: 47–52PubMedCrossRefGoogle Scholar
  54. Zeise ML, Madamba SG, Siggins GR, Putzke J, Zieglgänsberger W (1994) The anti-craving substance acamprosate reduces glutamatergic synaptic transmission and a high-treshold calcium current in neocortical and hippocampal pyramidal neurons. Alcohol Clin Exp Res 18: 36A (abtract no 5.33)Google Scholar
  55. Zielglgänsberger W, Zeise M (1992) Calcium-diacetyl-homotaurinate which prevents relapse in weaned alcoholics decreases the action of excitatory amino acids in neocortical neurons of the rat in vitro. In: Sellers EM, Naranjo CA (eds) Novel pharmacological interventions for alcoholism. Springer, Berlin Heidelberg New York, pp 337–341CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Soyka
    • 1
  1. 1.Psychiatrische KlinikLudwig-Maximilians-UniversitätMünchenGermany

Personalised recommendations